Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 08/25 05:30:49 pm
77.3 CHF   -1.47%
08/25 NOVARTIS' : phase III MS study successfully meets endpoints
08/25 NOVARTIS : announces positive phase III results showing efficacy of ..
08/24 NOVARTIS AG (NY : NVS) Licenses LGT209 To Cyon Therapeutics, Inc., T..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
08/19/2016 08/22/2016 08/23/2016 08/24/2016 08/25/2016 Date
77.95(c) 78.15(c) 78.6(c) 78.45(c) 77.3(c) Last
3 217 488 4 032 776 3 714 061 3 318 156 4 904 062 Volume
-0.64% +0.26% +0.58% -0.19% -1.47% Change
More quotes
Financials ($)
Sales 2016 48 839 M
EBIT 2016 11 381 M
Net income 2016 7 463 M
Debt 2016 14 751 M
Yield 2016 3,50%
Sales 2017 50 183 M
EBIT 2017 12 282 M
Net income 2017 8 670 M
Debt 2017 14 414 M
Yield 2017 3,68%
P/E ratio 2016 23,72
P/E ratio 2017 21,59
EV / Sales2016 4,68x
EV / Sales2017 4,55x
Capitalization 213 882 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, Vaccines & Diagnostics, and Consumer Health.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical,... 
Sector
Pharmaceuticals
Calendar
09/15Presentation
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
08/25 NOVARTIS' : phase III MS study successfully meets endpoints
08/25 NOVARTIS : announces positive phase III results showing efficacy of BAF312 in pa..
08/24 NOVARTIS AG (NYSE : NVS) Licenses LGT209 To Cyon Therapeutics, Inc., Teams Up Wi..
08/24 NOVARTIS : Today's Cartoon (August 24 2016)
08/23 NOVARTIS : Kenya Red Cross Society and Novartis Join Forces
08/22DJEli Lilly, AstraZeneca Progress With Alzheimer's Drug
08/19 NOVARTIS : Alcon Research Assigned Patent
08/18 NOVARTIS : New drugs hope to fight neglected tropical diseases
08/18 JACOBS ENGINEERING : Awarded Contract for Novartis Biotechnology Center Expansio..
08/18 NOVARTIS : Patent Issued for Combination Therapy (USPTO 9408847)
More news
Sector news : Pharmaceuticals - NEC
08/25 FTSE retreats as pharma stocks fall
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting -- 3rd Update
08/25DJMylan Boosts Price Assistance for EpiPen Amid Backlash
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/25 Siponimod Rides To Novartis' Rescue
08/25 Teva Holds Cracking Door On Copaxone Generics
08/25 Novartis' BAF312 successful in late-stage multiple sclerosis study
08/23 Who's Next After Medivation?
08/22 Finding And Owning The Best Businesses In The World
Advertisement
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 89,5 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-9.45%213 882
JOHNSON & JOHNSON15.57%324 776
ROCHE HOLDING LTD.-11.47%217 694
PFIZER INC.7.87%211 206
MERCK & CO., INC.18.76%173 462
GLAXOSMITHKLINE PLC21.19%106 869
More Results